These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 31181988)

  • 1. Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease.
    Benschop RJ; Chow CK; Tian Y; Nelson J; Barmettler B; Atwell S; Clawson D; Chai Q; Jones B; Fitchett J; Torgerson S; Ji Y; Bina H; Hu N; Ghanem M; Manetta J; Wroblewski VJ; Lu J; Allan BW
    MAbs; 2019; 11(6):1175-1190. PubMed ID: 31181988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
    Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
    MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of concurrent target suppression by JNJ-61178104, a bispecific antibody against human tumor necrosis factor and interleukin-17A.
    Zheng S; Shen F; Jones B; Fink D; Geist B; Nnane I; Zhou Z; Hall J; Malaviya R; Ort T; Wang W
    MAbs; 2020; 12(1):1770018. PubMed ID: 32544369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineering of stable bispecific antibodies targeting IL-17A and IL-23.
    Mabry R; Lewis KE; Moore M; McKernan PA; Bukowski TR; Bontadelli K; Brender T; Okada S; Lum K; West J; Kuijper JL; Ardourel D; Franke S; Lockwood L; Vu T; Frank A; Appleby MW; Wolf A; Reardon B; Hamacher NB; Stevens B; Lewis P; Lewis KB; Gilbertson DG; Lantry M; Julien SH; Ostrander C; Chan C; Byrnes-Blake K; Brody J; Presnell S; Meengs B; Levin SD; Snavely M
    Protein Eng Des Sel; 2010 Mar; 23(3):115-27. PubMed ID: 20022918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A bispecific antibody that targets IL-6 receptor and IL-17A for the potential therapy of patients with autoimmune and inflammatory diseases.
    Lyman M; Lieuw V; Richardson R; Timmer A; Stewart C; Granger S; Woods R; Silacci M; Grabulovski D; Newman R
    J Biol Chem; 2018 Jun; 293(24):9326-9334. PubMed ID: 29678878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and preclinical evaluation of KYS202004A, a novel bispecific fusion protein targeting TNF-α and IL-17A, in autoimmune disease models.
    Liu Z; Song L; Yang J; Liu H; Zhang Y; Pi X; Yan Y; Chen H; Yu D; Yin C; Liu T; Li X; Zhang C; Li D; Wang Z; Xiao W
    Int Immunopharmacol; 2024 Jul; 136():112383. PubMed ID: 38843642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanocell targeting using engineered bispecific antibodies.
    Taylor K; Howard CB; Jones ML; Sedliarou I; MacDiarmid J; Brahmbhatt H; Munro TP; Mahler SM
    MAbs; 2015; 7(1):53-65. PubMed ID: 25523746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F.
    Adams R; Maroof A; Baker T; Lawson ADG; Oliver R; Paveley R; Rapecki S; Shaw S; Vajjah P; West S; Griffiths M
    Front Immunol; 2020; 11():1894. PubMed ID: 32973785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CDR-restricted engineering of native human scFvs creates highly stable and soluble bifunctional antibodies for subcutaneous delivery.
    Fennell BJ; McDonnell B; Tam AS; Chang L; Steven J; Broadbent ID; Gao H; Kieras E; Alley J; Luxenberg D; Edmonds J; Fitz LJ; Miao W; Whitters MJ; Medley QG; Guo YJ; Darmanin-Sheehan A; Autin B; Shúilleabháin DN; Cummins E; King A; Krebs MR; Grace C; Hickling TP; Boisvert A; Zhong X; McKenna M; Francis C; Olland S; Bloom L; Paulsen J; Somers W; Jensen A; Lin L; Finlay WJ; Cunningham O
    MAbs; 2013; 5(6):882-95. PubMed ID: 23995618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization and analysis of scFv-IgG bispecific antibody size variants.
    Cao M; Wang C; Chung WK; Motabar D; Wang J; Christian E; Lin S; Hunter A; Wang X; Liu D
    MAbs; 2018; 10(8):1236-1247. PubMed ID: 30130449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A bispecific transmembrane antibody simultaneously targeting intra- and extracellular epitopes of the epidermal growth factor receptor inhibits receptor activation and tumor cell growth.
    Müller N; Hartmann C; Genssler S; Koch J; Kinner A; Grez M; Wels WS
    Int J Cancer; 2014 Jun; 134(11):2547-59. PubMed ID: 24243620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and optimization of a novel anti-GUCY2c x CD3 bispecific antibody for the treatment of solid tumors.
    Root AR; Guntas G; Katragadda M; Apgar JR; Narula J; Chang CS; Hanscom S; McKenna M; Wade J; Meade C; Ma W; Guo Y; Liu Y; Duan W; Hendershot C; King AC; Zhang Y; Sousa E; Tam A; Benard S; Yang H; Kelleher K; Jin F; Piche-Nicholas N; Keating SE; Narciandi F; Lawrence-Henderson R; Arai M; Stochaj WR; Svenson K; Mosyak L; Lam K; Francis C; Marquette K; Wroblewska L; Zhu HL; Sheehan AD; LaVallie ER; D'Antona AM; Betts A; King L; Rosfjord E; Cunningham O; Lin L; Sapra P; Tchistiakova L; Mathur D; Bloom L
    MAbs; 2021; 13(1):1850395. PubMed ID: 33459147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fab-based bispecific antibody formats with robust biophysical properties and biological activity.
    Wu X; Sereno AJ; Huang F; Lewis SM; Lieu RL; Weldon C; Torres C; Fine C; Batt MA; Fitchett JR; Glasebrook AL; Kuhlman B; Demarest SJ
    MAbs; 2015; 7(3):470-82. PubMed ID: 25774965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition.
    Croasdale R; Wartha K; Schanzer JM; Kuenkele KP; Ries C; Mayer K; Gassner C; Wagner M; Dimoudis N; Herter S; Jaeger C; Ferrara C; Hoffmann E; Kling L; Lau W; Staack RF; Heinrich J; Scheuer W; Stracke J; Gerdes C; Brinkmann U; Umana P; Klein C
    Arch Biochem Biophys; 2012 Oct; 526(2):206-18. PubMed ID: 22464987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of an ICOSL and BAFF bispecific inhibitor AMG 570 for systemic lupus erythematosus treatment.
    Zhang M; Lee F; Knize A; Jacobsen F; Yu S; Ishida K; Miner K; Gaida K; Whoriskey J; Chen C; Gunasekaran K; Hsu H
    Clin Exp Rheumatol; 2019; 37(6):906-914. PubMed ID: 30789152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Full-length recombinant antibodies from
    Rashid MH
    MAbs; 2022; 14(1):2111748. PubMed ID: 36018829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.
    Schanzer JM; Wartha K; Croasdale R; Moser S; Künkele KP; Ries C; Scheuer W; Duerr H; Pompiati S; Pollman J; Stracke J; Lau W; Ries S; Brinkmann U; Klein C; Umana P
    J Biol Chem; 2014 Jul; 289(27):18693-706. PubMed ID: 24841203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A modular IgG-scFv bispecific antibody topology.
    Orcutt KD; Ackerman ME; Cieslewicz M; Quiroz E; Slusarczyk AL; Frangioni JV; Wittrup KD
    Protein Eng Des Sel; 2010 Apr; 23(4):221-8. PubMed ID: 20019028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stabilization of the single-chain fragment variable by an interdomain disulfide bond and its effect on antibody affinity.
    Zhao JX; Yang L; Gu ZN; Chen HQ; Tian FW; Chen YQ; Zhang H; Chen W
    Int J Mol Sci; 2010 Dec; 12(1):1-11. PubMed ID: 21339972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bispecific single-chain diabody-immunoliposomes targeting endoglin (CD105) and fibroblast activation protein (FAP) simultaneously.
    Rabenhold M; Steiniger F; Fahr A; Kontermann RE; Rüger R
    J Control Release; 2015 Mar; 201():56-67. PubMed ID: 25617725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.